BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kohtala S. Ketamine-50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacol Rep 2021;73:323-45. [PMID: 33609274 DOI: 10.1007/s43440-021-00232-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Fukushima AR, Navas-suárez PE, Peña Muñoz JW, Ricci EL, Leoni LAB, Caperuto ÉC, Yanase L, Santana J, de França E, Delorenzi JCMOB, Terrivel AF, Ferreira GM, Hirata MH, Pantaleon LDP, Zacarelli-magalhães J, de Abreu GR, Waziry PAF, Nicoletti MA, Spinosa HDS. Post-Partum Depression Lactating Rat Model for Evaluating Ketamine’s Safety as a Pharmacotherapeutic Treatment: Roles in Cardiac and Urinary Function. JCDD 2022;9:299. [DOI: 10.3390/jcdd9090299] [Reference Citation Analysis]
2 La Via L, Sanfilippo F, Cuttone G, Dezio V, Falcone M, Brancati S, Crimi C, Astuto M. Use of ketamine in patients with refractory severe asthma exacerbations: systematic review of prospective studies. Eur J Clin Pharmacol 2022. [PMID: 36008492 DOI: 10.1007/s00228-022-03374-3] [Reference Citation Analysis]
3 Downing RA. The One Health vision requires veterinarians and physicians to collaborate to prevent bioethical challenges created by restricted access to ketamine in low- and middle-income countries. javma 2022. [DOI: 10.2460/javma.22.04.0182] [Reference Citation Analysis]
4 Le TT, Cordero IP, Jawad MY, Swainson J, Di Vincenzo JD, Jaberi S, Phan L, Lui LMW, Ho R, Rosenblat JD, McIntyre RS. The abuse liability of ketamine: A scoping review of preclinical and clinical studies. J Psychiatr Res 2022;151:476-96. [PMID: 35623124 DOI: 10.1016/j.jpsychires.2022.04.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Kritzer MD, Pae CU, Masand PS. Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability. Expert Opin Drug Saf 2022;:1-8. [PMID: 35475388 DOI: 10.1080/14740338.2022.2069749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Weiss M, Siegmund W. Pharmacokinetic Modeling of Ketamine Enantiomers and Their Metabolites After Administration of Prolonged-Release Ketamine With Emphasis on 2,6-Hydroxynorketamines. Clin Pharmacol Drug Dev 2021. [PMID: 34265182 DOI: 10.1002/cpdd.993] [Reference Citation Analysis]
7 Martinotti G, Chiappini S, Pettorruso M, Mosca A, Miuli A, Di Carlo F, D'Andrea G, Collevecchio R, Di Muzio I, Sensi SL, Di Giannantonio M. Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature. Brain Sci 2021;11:856. [PMID: 34199023 DOI: 10.3390/brainsci11070856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kohtala S, Rantamäki T. Rapid-acting antidepressants and the regulation of TrkB neurotrophic signalling-Insights from ketamine, nitrous oxide, seizures and anaesthesia. Basic Clin Pharmacol Toxicol 2021;129:95-103. [PMID: 33973360 DOI: 10.1111/bcpt.13598] [Reference Citation Analysis]